Login to Your Account

Clinic Roundup

Friday, March 15, 2013
• Oculus Innovative Sciences Inc., of Petaluma, Calif., completed a 112-day follow-up period in a trial of Microcyn Technology-based hydrogel for hypertrophic or keloid scars in 40 patients.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription